A linkup with an artificial intelligence player helped power shares of a top cloud-computing services company higher Monday, while an acquisition in the consumer goods space sent the two stocks on divergent paths.
Major U.S. equities indexes ended the first trading day of November mixed, kicking off a market week that will bring a wave of big-name quarterly reports. The S&P 500 added 0.2%, while the Nasdaq was up 0.5%. The Dow ended the session 0.5% lower.
IDEXX Laboratories (IDXX) shares jumped 15%, the best performance on the S&P 500 today, after the pet health specialist reported better-than-expected third quarter sales and profit. The company raised its 2025 revenue and earnings per share guidance, highlighting global customer adoption of its new diagnostic tools, which IDEXX says can help veterinarian teams increase clinical insights and streamline their workflows.
Paper products giant Kimberly-Clark (KMB) said it would buy Tylenol, Band-Aid, and Listerine parent company Kenvue (KVUE) in a cash-and-stock deal valued at around $49 billion. Kenvue, which completed a spin-off from Johnson & Johnson (JNJ) in 2023, has been navigating litigation over allegations that its talcum powder causes cancer and statements from the Trump administration linking Tylenol to autism.
Kenvue shares rose more than 12% Monday following the announcement of the deal, which came at a significant premium to Friday's closing price for Kenvue stock, while Kimberly-Clark shares plunged more than 14%. The latter company's shares were the worst performers on the S&P 500 today.
Amazon (AMZN) shares jumped 5% after ChatGPT owner OpenAI signed an agreement to buy more than $38 billion worth of capacity its Amazon Web Services cloud unit. OpenAI said the deal to use AWS infrastructure would provide it with access to a significant number of Nvidia (NVDA) graphics processing units that could be employed to train its AI models. Nvidia shares gained 2.2%.
Moderna (MRNA) stock sank 8.3% Monday, reversing a portion of the gains posted last week amid reports that the vaccine maker had held strategic talks with a major pharmaceutical company about a potential partnership or sale. Waning enthusiasm around a possible deal and concerns about the company's financial situation overshadowed Moderna's announcement that it administered the first dose in an early stage study of its experimental multiple myeloma therapy.
KeyBanc downgraded Charter Communications (CHTR) stock to "sector weight" from "overweight" after the cable and internet provider reported lower-than-expected third-quarter sales and profit in its most-recent quarterly release. Analysts cited competitive headwinds to Charter's broadband subscriber growth, which can affect its free cash flow. Its stock fell about 5%.
Source: Investopedia
Copyright © 2025 FastBull Ltd
News, historical chart data, and fundamental company data are provided by FastBull Ltd.
Risk Warnings and Disclaimers
You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.